

## RADIATION FORUM

CHELSEA HOTEL, TORONTO, ON  
ROOM: ROSSETTI

FRIDAY APRIL 25, 2025 8:00 AM – 12:00 PM

CHAIR : SCOTT MORGAN  
SENIOR INVESTIGATOR: WENDY PARULEKAR

### CME Credits:

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

### Learning Objectives:

- To integrate current knowledge regarding molecular biology and new therapeutics in clinical trials evaluating radiotherapy.
- To review relevant data from clinical studies evaluating radiotherapy interventions conducted by the Canadian Cancer Trials Group or its collaborators.
- To integrate optimal statistical methodologies in clinical trial design.
- To provide a learning environment supportive to investigators.

**8:00 am Welcome and Introductions**

**S. Morgan**

### CCTG Led and Intergroup Ongoing Trials Previously Presented

**8:05 am PR.22/ANZUP 1801  
BRC.8/S1827  
MAC.28/NRG BR007  
MA.39  
CE.7  
PR.19  
PR.20  
HN.9**

**S. Morgan  
J. Greenland  
V. Theberge  
V. Theberge  
D. Roberge  
E. Vigneault  
P. Cheung  
S. Morgan**

**8:35 am Recently Activated CCTG Studies**

Optimizing Head and Neck Tumour And Symptom Control in Patients Unable to Tolerate Curative Intent RT: A Phase III Trial Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study). **HN.13**

**I. Poon**

A Randomized Phase 3 Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases. **SC.29**

**T. Nguyen**

RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial **EN.11**

**S. Welch**



	Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT). <b>PR.24</b>	<b>A. Loblaw</b>
	SPECT-CT Guided ELEctive Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial. <b>HN.11</b>	<b>A. Hosni</b>
<b>9:25 am</b>	<u><i>CCTG Approved Studies Pending Activation</i></u>	
	A Randomized Phase II Trial of Delayed, Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with Low Risk HPV Related Oropharynx Cancer. <b>HN.14</b>	<b>A. McPartlin</b>
	Hypofractionated Alternative Radiation with MODulation of Neoadjuvant/perioperative immunotherapY in Sarcoma (HARMONY). <b>SR.8</b>	<b>P. Wong</b>
<b>9:45 am</b>	<b>BREAK</b>	
<b>10:00 am</b>	A Phase II Study of Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER). <b>EN.10</b>	<b>K. Han</b>
<b>10:10 am</b>	<u><i>New Study Proposals</i></u>	
	Stereotactic Ablative Radiotherapy for Locally Recurrent Prostate Cancer with Rectal Hydrogel Spacer	<b>A. Taggar</b>
	Integrating image-guided HDR brachytherapy in non-operative management of rectal cancer (IGNITE) – phase II RCT trial concept	<b>A. Taggar</b>
	Preoperative/Neoadjuvant Stereotactic Radiosurgery Followed by Brain Metastases Resection: A Single-Institute Pilot Study	<b>V. Pareek</b>
	SBRT Versus Conventional Fractionation in Prostate Bed Salvage Radiation: A Phase III Randomized Trial	<b>V. Pareek</b>
	NRG-GI012: Randomized Phase III Study of Systemic Therapy +/- Liver SBRT in Hepatocellular Cancer with Macrovascular Invasion (HELIO-RT)	<b>L. Dawson</b>
	Single fraction risk-adapted radiotherapy for treatment refractory or end stage liver cancer: A randomized control trial	<b>L. Dawson</b>
	Lattice Radiation Therapy versus Conventional Radiation Therapy for the Palliation of Large Tumors (LATTICE-PAL)	<b>J. Lukovic</b>
	Phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs moderately hypofractionated external beam radiotherapy for biochemical recurrence following surgery in prostate cancer. (PACE Post-op trial)	<b>E. Tseng</b>
	A Pragmatic Randomized Trial Comparing Weekly Docetaxel to Cisplatin in Patients with Locally Advanced Head & Neck Cancer Treated with Radiation	<b>E. Winquist</b>
	DIRECT- duration of ARPI and ADT with metastasis directed therapy in oligometastatic cancer of the prostate	<b>R. Glicksman</b>



**11:45 am**    CCTG Recently Activated Study

Consolidative Use Of Radiotherapy To Block (CURB2) Oligoprogression In  
Patients With Metastatic Non-Small-Cell Lung Cancer – A Randomized Phase 3  
Trial. **BR.38**

**A. Sun**

**11:55 am**    **Radiation Oncology Quality Assurance Committee**

**A. Nichol**

**12:00pm**    **Meeting Adjourned**



Canadian Cancer Society  
Société canadienne  
du cancer

CCTG is a CCS national program.